Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case 33% Improvement Relative Risk c19early.org/mf Milosavljevic et al. Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19
Milosavljevic et al., Journal of Community Hospital Internal Medicine Perspectives, doi:10.55729/2000-9666.1127
Milosavljevic et al., Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes.., Journal of Community Hospital Internal Medicine Perspectives, doi:10.55729/2000-9666.1127
Nov 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 733 hospitalized COVID-19 patients with diabetes in the USA, showing lower risk of severity with metformin use.
risk of severe case, 33.0% lower, OR 0.67, p = 0.03, treatment 377, control 356, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Milosavljevic et al., 9 Nov 2022, retrospective, USA, peer-reviewed, mean age 67.4, 7 authors, study period 1 March, 2020 - 31 December, 2020.
Contact: jovmilosa@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Journal of Community Hospital Internal Medicine Perspectives Volume 12 Issue 6 Article 5 2022 Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19 Jovan Milosavljevic Department of Medicine, Sinai Hospital of Baltimore, Baltimore, jovmilosa@gmail.com Navya Reddy Perkit Department of Medicine, Sinai Hospital of Baltimore, Baltimore Sakshi Jhawar Department of Medicine, Sinai Hospital of Baltimore, Baltimore Melbin Thomas Department of Medicine, Sinai Hospital of Baltimore, Baltimore Justin Ling Department of Medicine, Sinai Hospital of Baltimore, Baltimore See next page for additional authors Follow this and additional works at: https://scholarlycommons.gbmc.org/jchimp Recommended Citation Milosavljevic, Jovan; Perkit, Navya Reddy; Jhawar, Sakshi; Thomas, Melbin; Ling, Justin; Amankwah, Samuel; and Thomas, Asha Mary (2022) "Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19," Journal of Community Hospital Internal Medicine Perspectives: Vol. 12: Iss. 6, Article 5. DOI: 10.55729/2000-9666.1127 Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss6/5 This Research Article is brought to you for free and open access by the Journal at GBMC Healthcare Scholarly Commons. It has been accepted for inclusion in Journal of Community Hospital Internal Medicine Perspectives by an authorized editor of GBMC Healthcare Scholarly Commons. For more information, please contact GBMCcommons@gbmc.org. Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19 Authors Jovan Milosavljevic, Navya Reddy Perkit, Sakshi Jhawar, Melbin Thomas, Justin Ling, Samuel Amankwah, and Asha Mary Thomas This research article is available in Journal of Community Hospital Internal Medicine Perspectives: https://scholarlycommons.gbmc.org/jchimp/vol12/iss6/5 Jovan Milosavljevic a,*, Navya R. Perkit a, Sakshi Jhawar a, Melbin Thomas a, Justin Ling a, Samuel Amankwah a, Asha M. Thomas b a b Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA Division of Endocrinology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA Abstract Objectives: To identify risk factors for severe disease and death among patients with diabetes and coronavirus disease 2019 (COVID-19) infection. Methods: This retrospective cohort study conducted at three hospitals included 733 consecutive patients with DM admitted with confirmed COVID-19 (March 1 - December 31, 2020). Multivariable logistic regression was performed to identify predictors of severe disease and death. Results: The mean age was 67.4 ± 14.3 years, 46.9% were males and 61.5% were African American. Among all patients, 116 (15.8%) died in the hospital. A total of 317 (43.2%) patients developed severe disease, 183 (25%) were admitted to an ICU and 118 (16.1%) required invasive mechanical ventilation. Increasing BMI (OR, 1.13; 95% CI, 1.02e1.25), history of chronic lung disease (OR, 1.49; 95% CI, 1.05e2.10) and increasing time since the last HbA1c test (OR, 1.25; 95% CI, 1.05e1.49) were the preadmission factors associated with increased odds of severe disease. Preadmission use of metformin (OR, 0.67; 95% CI, 0.47e0.95) or GLP-1 agonists (OR, 0.49; 95% CI, 0.27e0.87) was associated with decreased odds of severe disease. Increasing age (OR, 1.21; 95% CI,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit